Summit Therapeutics (NASDAQ:SMMT) stock extends gains as lead cancer drug ivonescimab developed with Akeso (AKESF) ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on ...

BeiGene stock has formed an early-stage base with a buy point of 287.88 ahead of its first-quarter results on May 7.

Akeso Pharmaceuticals and Summit Therapeutics have reported that their PD-1/VEGF bispecific antibody has met the primary ...

Analysts have set 12-month price targets for BeiGene, revealing an average target of $330.25, a high estimate of $348.00, and a low estimate of $312.00. This current average reflects an increase of 10 ...

This obligation is derived from the “considerable effort” needed to demonstrate safety, quality and efficacy of an innovative ...

Beigene (NASDAQ:ONC – Free Report) had its target price raised by JPMorgan Chase & Co. from $311.00 to $317.00 in a report published on Monday,Benzinga reports.JPMorgan Chase & Co. currently has ...

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of lung cancer.

We’ve lowered our fair value estimate of Snap-on stock. We sell different types of products and services to both investment professionals and individual investors. These products and services ...

SAN CARLOS, Calif. — BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of ...